Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 23 December 2015 | By Zachary Brennan
For manufacturers of non-reproductive human cells, tissues, and cellular and tissue-based products (HCT/Ps), FDA released draft guidance on Wednesday outlining the most frequently reported HCT/P deviations reported to the Center for Biologics Evaluation and Research (CBER).
Under FDA’s authority, a manufacturer of non-reproductive HCT/Ps must investigate and report to the agency all HCT/P deviations related to a distributed product for which the establishment performed a manufacturing step.
The reports have to come within 45 days of the discovery of the event.
The look into which deviations are most frequently reported, as well as examples of which deviations are reportable and non-reportable, comes in addition to FDA’s descriptive scenarios illustrating who must report, what must be reported, and when such reports must be submitted.
FDA has seen a rising number inspections of HCT/P manufacturers over the last decade, and has publically disclosed an untitled letter and a warning letter to such companies in recent years, as well as additional guidance in 2014 and an update on adverse event reporting requirements from earlier this year.
The first HCT/P deviation examples look at companies which distributed an HCT/P and then discovered that it was obtained from an ineligible donor:
As far as examples of non-reportable findings related to donor eligibility, FDA points to:
The following are reportable deviations for donor screening:
As far as examples of non-reportable findings related to donor screening, FDA says:
Examples of companies testing a donor specimen for evidence of infection due to communicable disease agents and finding deviations include:
Examples of non-reportable findings related to donor testing include:
For companies processing each HCT/P in ways that do not cause contamination or cross-contamination, examples of deviations include:
Examples of non-reportable findings related to processing and process controls include:
And finally, as far as examples of reportable HCT/P deviations related to receipt, pre-distribution, shipment and distribution, FDA says:
Examples of non-reportable findings for such products include:
Draft Guidance on Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products
Tags: HTC/P, deviation reports
Regulatory Focus newsletters
All the biggest regulatory news and happenings.